The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks National Cancer Institute (NCI) designation via the P30 Cancer Center Support Grant mechanism to support its mission to reduce the cancer burden in South Carolina and beyond. As South Carolina's leading academic medical center, MUSC has been charged and supported over the past decade to build clinical, basic, translational and population-based research programs that address the state's significant cancer morbidity and mortality. Through the support of an NCI P20 Planning Grant (2001-2007), the HCC has recruited and organized 97 cancer scientists, representing six MUSC Colleges - Medicine, Pharmacy, Dental Medicine, Nursing, Health Professions and Graduate Studies - into productive and collaborative cancer research programs. These programs are: Lipid Signaling in Cancer, Cancer Genes & Molecular Regulation, Developmental Cancer Therapeutics and Cancer Immunology. A Cancer Prevention & Control program is in development. The HCC has expanded and continues to expand its research facilities and resources to enhance further growth. In 2006, the HCC completed a seven story tower adjacent to its original 85,761 ft2 building adding more than 116,000 ft2 in research, clinical and administrative space, and MUSC has committed an additional 62,000 ft2 of research space to the HCC in two new buildings starting construction in summer 2008. As part of this P30 application, five shared research resources will be presented: Lipidomics, Flow Cytometry & Cell Sorting, Cell & Molecular Imaging, Biostatistics and Clinical Trials. The HCC has invested $1.6M since 2004 into enhancing these five essential and critical resources. Given the rapid and ongoing development of research in the programs, the HCC has also invested another $6M in initiating the development and optimizing the function of seven other shared resources that will greatly impact on HCC's current and future programmatic-based research initiatives. These investments have resulted in a doubling of the HCC's extramural research funding base since 2003, currently $31.2M with NCI funding representing $12.1M. Accrual to therapeutic clinical trials has quadrupled in the same time period. This application demonstrates that HCC scientists have made significant contributions to the understanding of cancer biology and the development of novel approaches to prevent, diagnose and treat cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-03
Application #
8249930
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
3
Fiscal Year
2011
Total Cost
$141,484
Indirect Cost
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Wolfe, A M; Dunlap, K M; Smith, A C et al. (2018) Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination. J Virol 92:
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162
Graboyes, Evan M; Kompelli, Anvesh R; Neskey, David M et al. (2018) Association of Treatment Delays With Survival for Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg :
Bai, Aiping; Bielawska, Alicja; Rahmaniyan, Mehrdad et al. (2018) Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites. Bioorg Med Chem 26:6067-6075
Bea, Vivian J; Cunningham, Joan E; Alberg, Anthony J et al. (2018) Alcohol and Tobacco Use in an Ethnically Diverse Sample of Breast Cancer Patients, Including Sea Island African Americans: Implications for Survivorship. Front Oncol 8:392
Burris, Jessica L; Rivera-Rivera, Jessica N; Armeson, Kent et al. (2018) Causal attributions and their impact on psychosocial functioning in head and neck cancer patient-caregiver dyads: a preliminary, longitudinal study. Qual Life Res :
Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704
Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800
Jin, Junfei; Lu, Zhongyang; Li, Yanchun et al. (2018) LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. J Leukoc Biol 104:843-853
Janakiraman, Harinarayanan; House, Reniqua P; Gangaraju, Vamsi K et al. (2018) The Long (lncRNA) and Short (miRNA) of It: TGF?-Mediated Control of RNA-Binding Proteins and Noncoding RNAs. Mol Cancer Res 16:567-579

Showing the most recent 10 out of 536 publications